Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment
- PMID: 37749188
- DOI: 10.1038/s41409-023-02107-z
Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment
Abstract
We conducted a prospective study aimed at investigating the prognostic value of the dynamic of a-GVHD progression from cutaneous to visceral involvement. In 108 consecutive patients who underwent allogeneic HSCT, we classified a-GVHD according to a "GHVD skin dynamic": 18/82 patients started Corticosteroid (CS) within 48 h (Group 1); 13/82 started CS within days 3-7 (Group 2); Group 3A (n 31) was defined when Skin GVHD Overall Grade 1, left untreated for 1 week, showed an increase in involved body surface area <5 %; Group 3B (n 20), was defined when Skin GVHD Overall Grade 1, left untreated at 1 week, had an increase in involved body surface area >5%. These four groups had distinctive 2-y OS. Patients could be then grouped into "poor risk" (Group 1 and Group 3B) and "good risk" (Group 2 and Group 3A). "Poor risk" had inferior OS in univariate and multivariate analysis, (HR 2.222; 95% CL: 1.017-4.855; p 0.04). Among the patients with skin-only Grade 1 GVHD, subgroup 3A had an OS of 75.1% versus 39.8% found in subgroup 3B (p = 0.03). The dynamic of skin GVHD may be used to classify a-GVHD and guide treatment in Overall Grade 1 skin-only GVHD.
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin.Ann Hematol. 2018 Jan;97(1):169-179. doi: 10.1007/s00277-017-3141-4. Epub 2017 Sep 30. Ann Hematol. 2018. PMID: 28965134
-
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.Lancet Haematol. 2019 Aug;6(8):e409-e418. doi: 10.1016/S2352-3026(19)30088-2. Epub 2019 Jun 24. Lancet Haematol. 2019. PMID: 31248843 Free PMC article. Clinical Trial.
-
Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.Transpl Infect Dis. 2020 Feb;22(1):e13217. doi: 10.1111/tid.13217. Epub 2019 Dec 9. Transpl Infect Dis. 2020. PMID: 31769584
-
Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.Blood. 2020 Oct 22;136(17):1903-1906. doi: 10.1182/blood.2020007336. Blood. 2020. PMID: 32756949 Review.
-
Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.Stem Cell Res Ther. 2020 Feb 18;11(1):64. doi: 10.1186/s13287-020-01592-z. Stem Cell Res Ther. 2020. PMID: 32070420 Free PMC article.
References
-
- Dalle JH, Giralt SA. Hepatic Veno-Occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl. 2016;22:400–9. https://doi.org/10.1016/j.bbmt.2015.09.024 . - DOI
-
- Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, et al. Noninfectious pulmonary toxicity after allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:310–20. https://doi.org/10.1016/j.jtct.2022.03.015 . - DOI - PubMed - PMC
-
- Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. https://doi.org/10.1097/00007890-197410000-00001 . - DOI - PubMed
-
- Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources